-transparent.png){kind=logo}
By the US Food and Drug Administration spironolactone is regarded as a drug with problems related to bioavailability. A steady-state study was performed comparing the 50- and 100-mg formulations of two manufacturers with each other. Applying a fluorimetric method to both canrenone and canrenoate--the major biologically active metabolites of spironolactone--the two brands were compared in 11 volunteers for the 50 mg, and in 10 volunteers for the 100 mg dosage form.
Related Publications
J Rosenthal, and
H Jaeger, and
M Specker
March 1979,
Kokyu to junkan. Respiration & circulation,
J Rosenthal, and
H Jaeger, and
M Specker
January 1979,
Arzneimittel-Forschung,
J Rosenthal, and
H Jaeger, and
M Specker
May 1977,
Clinical pharmacology and therapeutics,
J Rosenthal, and
H Jaeger, and
M Specker
May 1981,
Clinical pharmacology and therapeutics,
J Rosenthal, and
H Jaeger, and
M Specker
January 1974,
Respiration; international review of thoracic diseases,
J Rosenthal, and
H Jaeger, and
M Specker
January 1973,
Bulletin de physio-pathologie respiratoire,
J Rosenthal, and
H Jaeger, and
M Specker
January 1987,
Biopharmaceutics & drug disposition,
J Rosenthal, and
H Jaeger, and
M Specker
September 1973,
Ceskoslovenska gynekologie,
J Rosenthal, and
H Jaeger, and
M Specker
September 1974,
Klinische Wochenschrift,
J Rosenthal, and
H Jaeger, and
M Specker
February 2006,
Experimental and clinical psychopharmacology,
